French order for Relenza triples cumulative global sales
11 November, 2005 by Ruth BeranA French government announcement that it would increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years has sent shares in Melbourne-based Biota Holding's (ASX:BTA) up by more than 20 per cent.
Solbec earns orphan drug status for carcinoma treatment
11 November, 2005 by Helen SchullerSolbec Pharmaceuticals (ASX:SBP) has received orphan drug designation from the US Food and Drug Administration for its lead anti-cancer compound Coramsine for the treatment of metastatic renal cell carcinoma (mRCC).
Incoming Mayne Pharma CEO sees growth through acquisitions
11 November, 2005 by Staff WritersThe incoming chief of Mayne Pharma, the global injectable drugs business soon to emerge from the break-up of Mayne Group (ASX:MAY), said growth would have to come from acquisitions and expansion into new areas.
Ventracor, Heartware settle patent dispute
10 November, 2005 by Helen SchullerArtificial heart firms Ventracor (ASX:VCR) and HeartWare (ASX:HTW) have settled a year-long patent dispute.
Tissue Therapies hopes new model can eliminate need for animal tests
09 November, 2005 by Graeme O'NeillIf beauty is skin deep, the latest wrinkle from Brisbane biotech Tissue Therapies (ASX:TIS) should hold deep allure for cosmetics companies -- the company's researchers have developed a live-skin model with the same structure and properties as human skin.
Why I got involved with the biotech code of practice
09 November, 2005 by Igor GondaThe new AusBiotech/ASX code of practice for reporting by life science companies, launched last week, is being hailed as an important milestone in the development of the Australian biotech sector. Here, Igor Gonda, who was on the committee to review the code's first draft, explains why he believes the code is so important to the industry.
Portland Orthopaedics to raise up to $5 million, list on ASX
08 November, 2005 by Helen SchullerHip replacement specialist Portland Orthopaedics has joined the growing list of companies who have lodged a prospectus to list on the ASX before Christmas.
Sunshine Heart gets thumbs-up for Australian pilot study
08 November, 2005 by Helen SchullerSunshine Heart (ASX:SHC) has received ethics committee approval to conduct implantations of its C-Pulse device in Australia at Southern Health Monash Medical Centre in Melbourne.
Epitan receives marketing approval for Zindaclin
08 November, 2005 by Ruth BeranEpitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin.
BresaGen to make Psiron melanoma therapy
08 November, 2005 by Graeme O'NeillSydney biotech Psiron (ASX:PSX) will be the first client for rejuvenated Adelaide biotechnology manufacturer BresaGen's new pilot production plant for therapeutics produced in mammalian cell cultures.
Acrux terminates Napa licence
08 November, 2005 by Ruth BeranAcrux DDS, a wholly owned subsidiary of Melbourne-based Acrux (ASX:ACR), has terminated an exclusive licence agreement it signed in May 2005 with US firm Napa Biosciences.
CyGenics acquires 51 per cent of BioCell
08 November, 2005 by Ruth BeranCell therapy company CyGenics (ASX:CYN) has taken a 51 per cent controlling equity interest in cord blood stem cell banking business BioCell.
Cytopia picks up $3m grant
08 November, 2005 by Graeme O'NeillMelbourne oncology drug developer Cytopia (ASX:CYT) has been offered a AUD$3 million federal government Commercial Ready grant to expand clinical development of its lead anti-cancer drug CYT997.
Panbio names new CEO
04 November, 2005 by Helen SchullerBrisbane medical diagnostics developer Panbio (ASX:PBO) has successfully completed a seven-month search for a new CEO in what executive chairman Jim Kalokerinos has described as a "longer process than hoped."
GTG, Applera look to be nearing settlement
04 November, 2005 by Graeme O'NeillMelbourne-based gene testing company Genetic Technologies (ASX:GTG, NASDAQ:GENE) appears to be nearing settlement of its long-running court case against US rival Applera Corp over Applera's refusal to take a licence to use GTG's patents on the use of so-called 'junk' DNA markers for gene testing.
